Pulse Biosciences, Inc. (PLSE) is a publicly traded company in the Unknown sector. Across all available filings, 11 corporate insiders have executed 252 transactions totaling $203.0M, demonstrating a bullish sentiment with $193.1M in net insider flow. The most recent transaction on Feb 18, 2026 involved a transaction of 5,000 shares valued at $0.
No significant insider buying has been recorded for PLSE in the recent period.
No significant insider selling has been recorded for PLSE in the recent period.
Based on recent SEC filings, insider sentiment for PLSE is bullish with an Insider Alignment Score of 98/100 and a net flow of $193.1M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Pulse Biosciences, Inc. (PLSE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 11 insiders are actively trading PLSE stock, having executed 252 transactions in the past 90 days. The most active insider is Robert W. Duggan (Executive), who has made 102 transactions totaling $267.3M.
Get notified when executives and directors at PLSE file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 5,000 | $N/A | $0 | |
| Feb 18, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Sale | 5,000 | $23.64 | $118.2K | |
| Feb 18, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 5,000 | $1.53 | $7.7K | |
| Feb 11, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Feb 11, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Sale | 20,000 | $25.20 | $504.0K | Large |
| Feb 11, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 20,000 | $1.53 | $30.6K | |
| Feb 10, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Feb 10, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Sale | 20,000 | $23.52 | $470.4K | |
| Feb 10, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 20,000 | $1.53 | $30.6K | |
| Feb 9, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 20,000 | $N/A | $0 | |
| Feb 9, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Sale | 20,000 | $21.45 | $429.0K | |
| Feb 9, 2026 | Patrick Danahy Kevin | Chief Commercial Officer | Option Exercise | 20,000 | $1.53 | $30.6K | |
| Feb 5, 2026 | Sainz Maria | Executive | Award | 3,104 | $N/A | $0 | |
| Jan 8, 2026 | Sainz Maria | Executive | Award | 50,000 | $N/A | $0 | |
| Oct 2, 2025 | Patrick Danahy Kevin | Executive | Option Exercise | 4,600 | $1.53 | $7.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 129 | $198.0M | 71.2% |
Exercise (Options)(X) | 65 | $72.8M | 26.2% |
Sale(S) | 17 | $4.9M | 1.8% |
Exercise(M) | 34 | $2.4M | 0.9% |
Payment(F) | 4 | $27.9K | 0.0% |
Award(A) | 3 | $0 | 0.0% |
Insiders at Pulse Biosciences, Inc. are accumulating shares at an accelerated pace. With 11 insiders making 252 transactions totaling $198.0M in purchases versus $4.9M in sales, the net buying activity of $193.1M signals strong executive confidence. Robert W. Duggan (Executive) leads the buying activity with $267.3M in transactions across all time.